Syndax Pharmaceuticals Inc. (Nasdaq: SNDX), a commercial-stage biopharmaceutical company, has released its financial results for the second quarter ended June 30, 2025. The company reported total revenue of $38.0 million for the quarter. This includes $28.6 million from Revuforj net product revenue, signifying a 43% growth over the first quarter of 2025. Additionally, Syndax recorded $9.4 million in Niktimvo collaboration revenue, derived from the $36.2 million in net revenue reported by its partner, Incyte. The net loss attributable to common stockholders for the quarter was $71.8 million, compared to a net loss of $68.1 million in the same period last year. Syndax had cash, cash equivalents, and short- and long-term investments totaling $517.9 million as of June 30, 2025. Looking ahead, Syndax expects its total research and development plus selling, general and administrative expenses to be between $95 and $100 million for the third quarter of 2025, excluding non-cash stock compensation expenses. For the full year 2025, these expenses are anticipated to be between $370 and $390 million, also excluding non-cash stock compensation expenses. The company is not providing revenue guidance at this time. Syndax anticipates that its cash, investments, product revenue, and interest income will support the company in achieving profitability. A notable update in the company's operations is the priority review granted for its sNDA in R/R mNPM1 AML, with a PDUFA action date set for October 25, 2025.